L3VLUP
ProSign in

BMY · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

BMYJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • BMY
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterBMYJNJ
Q3 202031 holders, $18.8bn30 holders, $26.2bn
Q4 202028 holders, $16.4bn32 holders, $26.6bn
Q1 202131 holders, $15.2bn31 holders, $25.3bn
Q2 202127 holders, $16.3bn37 holders, $25.6bn
Q3 202130 holders, $14.2bn40 holders, $24.1bn
Q4 202128 holders, $12.9bn33 holders, $25.2bn
Q1 202228 holders, $15.2bn35 holders, $28.2bn
Q2 202231 holders, $14.8bn33 holders, $26.9bn
Q3 202227 holders, $12.2bn36 holders, $25.4bn
Q4 202233 holders, $10.0bn35 holders, $27.6bn
Q1 202329 holders, $8.4bn42 holders, $24.5bn
Q2 202329 holders, $7.9bn38 holders, $25.0bn
Q3 202332 holders, $7.5bn37 holders, $18.9bn
Q4 202330 holders, $7.2bn31 holders, $19.0bn
Q1 202420 holders, $6.6bn32 holders, $19.7bn
Q2 202426 holders, $6.4bn35 holders, $20.4bn
Q3 202431 holders, $7.9bn28 holders, $22.3bn
Q4 202427 holders, $6.6bn37 holders, $20.4bn
Q1 202520 holders, $6.6bn32 holders, $20.5bn
Q2 202522 holders, $5.6bn31 holders, $18.4bn
Q3 202528 holders, $5.4bn32 holders, $23.7bn
Q4 202525 holders, $7.7bn29 holders, $27.8bn
Q1 202627 holders, $8.3bn34 holders, $35.6bn
Q2 202622 holders, $8.2bn33 holders, $39.1bn
BMY

Bristol-myers Squibb Co

Holders
25
Reported value
$7.7bn
Buyers
13
Sellers
27

Breadth -14 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
29
Reported value
$27.8bn
Buyers
13
Sellers
26

Breadth -13 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 37 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only BMY (8)

Balyasny Asset Management LLC, ExodusPoint Capital Management LP, Point72 Asset Management LP, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Steadfast Capital Management LP, Two Sigma Investments LP, Winton Group Ltd

Only JNJ (12)

Capital Research Global Investors, Capital World Investors, D. E. Shaw & Co., Element Capital Management LLC, Freestone Grove Partners LP, Hudson Bay Capital Management LP, Markel Group Inc, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Rokos Capital Management LLP, Squarepoint Ops LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →